Investec has raised its recommendation for banking group Barclays from 'add' to 'buy' and retained its 300p target price despite what is expected to be a 'lacklustre' third-quarter report on October 30th.Analyst Ian Gordon said that the upgrade is due to a combination of: passing rights issues-related headwinds; valuation support; strong expected future dividends; and a potential "over-delivery" of cost-reduction targets.Shares in GlaxoSmithKline (GSK) edged lower on Friday due to the possible negative readacross from US pharmaceuticals peer Eli Lilly, which warned about headwinds to its revenues in 2014. Nevertheless, Panmure Gordon maintained its upbeat stance on London-listed GSK, saying it would use any weakness in the stock as a 'buying' opportunity, given the "excellent option value provided by the pipeline".Jefferies has cut its target price for Tate & Lyle from 980p to 900p after a mixed second-quarter trading update from the sweeteners and ingredients firm on Friday.The broker continued: "Management reiterated the full-year outlook for 'another profitable year of growth' but the recent foreign exchange moves and a less favourable sucralose pricing environment are likely to drive low-single-digit consensus [earnings] downgrades, in our opinion."BC